Prenatal Medication Exposure Linked to Increased Autism Risk in Landmark Study

Apr 20, 2026

Researchers from the University of Nebraska Medical Center published a landmark study in Molecular Psychiatry analyzing over six million maternal-child health records from 2014-2023, representing one-third of all U.S. births during that period. The study found that prenatal exposure to sterol biosynthesis-inhibiting medications—including common antidepressants like fluoxetine and sertraline, beta-blockers like propranolol, and statins—increased autism spectrum disorder risk by 1.47-fold for one medication and 2.33-fold for four or more co-prescribed drugs. Exposure to these medications during pregnancy surged from 4.3% in 2014 to 16.8% in 2023, affecting growing numbers of pregnancies. The researchers linked the findings to disruption of cholesterol production critical for fetal brain development around 19-20 weeks of gestation, drawing parallels to Smith-Lemli-Opitz syndrome where 75% of affected children exhibit autism symptoms. While advocating for heightened clinical vigilance and integration of sterol metabolism assessments into drug development, researchers emphasized that patients should not abruptly stop prescribed treatments without medical guidance.

Landmark Study Linking Prenatal Medications to Autism Risk

▪Pregnant individuals prescribed at least one sterol biosynthesis-inhibiting medication faced a 1.47-fold increase in likelihood of delivering a child later diagnosed with autism spectrum disorder.
▪The University of Nebraska Medical Center study grouped prenatal medications by their shared biochemical interference rather than by clinical indications.
▪Prenatal sterol biosynthesis-inhibiting medication exposure increased from 4.3% of pregnancies in 2014 to 16.8% in 2023.
▪The Epic Cosmos database cohort used in the University of Nebraska Medical Center study represents roughly one-third of all U.S. births from 2014 through 2023.
▪Co-prescription of four or more sterol biosynthesis-inhibiting medications during pregnancy resulted in a 2.33 times higher autism spectrum disorder risk.
▪The University of Nebraska Medical Center study analyzed over six million maternal-child health records from the Epic Cosmos database.
▪The University of Nebraska Medical Center study examined 14 sterol biosynthesis-inhibiting medications including fluoxetine, sertraline, atorvastatin, and propranolol.

Sterol Biosynthesis Disruption and Fetal Brain Development

▪The University of Nebraska Medical Center study suggests pharmacologic interference of the sterol biosynthesis pathway may recapitulate aspects of vulnerability seen in Smith-Lemli-Opitz syndrome.
▪The period around 19 to 20 weeks of gestation is critical for synaptogenesis and circuit formation in the fetal brain.
▪The fetal brain commences autonomous sterol production around 19 to 20 weeks of gestation.
▪As many as 75% of children with Smith-Lemli-Opitz syndrome exhibit autism spectrum disorder symptomatology.

Clinical and Public Health Implications for Prenatal Care

▪The University of Nebraska Medical Center researchers advocate for heightened vigilance among healthcare providers regarding sterol biosynthesis-inhibiting medications during pregnancy.
▪The University of Nebraska Medical Center study authors state results should not lead to abrupt cessation of prescribed treatments without medical guidance.
▪The University of Nebraska Medical Center researchers propose identifying pregnant individuals with inherent genetic susceptibilities in sterol metabolism to tailor risk mitigation efforts.
▪The University of Nebraska Medical Center researchers propose constructing an exhaustive pharmacopeia identifying sterol-inhibiting agents.
▪The University of Nebraska Medical Center researchers propose integrating sterol metabolism assessments into the drug development pipeline.
▪The University of Nebraska Medical Center researchers propose enhanced education for clinicians about neurodevelopmental risks associated with sterol disruption during pregnancy.

Perspective of University of Nebraska Medical Center researchers

▪The University of Nebraska Medical Center study findings suggest that pharmacologic disruption of sterol biosynthesis during pregnancy may create neurodevelopmental vulnerabilities similar to genetic sterol metabolism disorders.

Perspective of Pregnant individuals prescribed sterol biosynthesis-inhibiting medications

▪The nearly fourfold increase in prenatal sterol biosynthesis-inhibiting medication exposure from 2014 to 2023 indicates growing numbers of pregnant individuals face these medication decisions.

Perspective of Pharmaceutical industry and drug developers

▪The identification of 14 commonly prescribed medications as sterol biosynthesis inhibitors may prompt pharmaceutical companies to develop alternative compounds without this mechanism of action.